Sartorius Stedim Biotech (DIM) Stock Overview
Engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DIM Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Sartorius Stedim Biotech S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €211.60 |
| 52 Week High | €239.80 |
| 52 Week Low | €148.75 |
| Beta | 0.89 |
| 1 Month Change | 16.71% |
| 3 Month Change | 20.91% |
| 1 Year Change | 12.08% |
| 3 Year Change | -34.59% |
| 5 Year Change | -35.01% |
| Change since IPO | 2,474.73% |
Recent News & Updates
Is Sartorius Stedim Biotech S.A. (EPA:DIM) Potentially Undervalued?
Oct 17
Is There An Opportunity With Sartorius Stedim Biotech S.A.'s (EPA:DIM) 21% Undervaluation?
Aug 29Recent updates
Is Sartorius Stedim Biotech S.A. (EPA:DIM) Potentially Undervalued?
Oct 17Is There An Opportunity With Sartorius Stedim Biotech S.A.'s (EPA:DIM) 21% Undervaluation?
Aug 29Is There Now An Opportunity In Sartorius Stedim Biotech S.A. (EPA:DIM)?
Jul 17Is Sartorius Stedim Biotech (EPA:DIM) A Risky Investment?
Jul 01What Sartorius Stedim Biotech S.A.'s (EPA:DIM) 30% Share Price Gain Is Not Telling You
May 10Results: Sartorius Stedim Biotech S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 19Is Now The Time To Look At Buying Sartorius Stedim Biotech S.A. (EPA:DIM)?
Apr 10Sartorius Stedim Biotech S.A. (EPA:DIM) Shares Could Be 25% Above Their Intrinsic Value Estimate
Mar 26Sartorius Stedim Biotech S.A.'s (EPA:DIM) Shareholders Might Be Looking For Exit
Feb 07Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?
Dec 27
Increased Order Intake And Efficiency Drive Future Growth Amidst Global Challenges
Increased order intake for consumables indicates future recurring revenue stability as customer destocking improves, highlighting positive growth trends.Sartorius Stedim Biotech's (EPA:DIM) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 25Shareholder Returns
| DIM | FR Life Sciences | FR Market | |
|---|---|---|---|
| 7D | 4.4% | 3.6% | 0.7% |
| 1Y | 12.1% | -1.4% | 8.7% |
Return vs Industry: DIM exceeded the French Life Sciences industry which returned -1.4% over the past year.
Return vs Market: DIM exceeded the French Market which returned 8.7% over the past year.
Price Volatility
| DIM volatility | |
|---|---|
| DIM Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 5.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 10.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: DIM has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: DIM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,134 | Rene Faber | www.sartorius.com |
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products.
Sartorius Stedim Biotech S.A. Fundamentals Summary
| DIM fundamental statistics | |
|---|---|
| Market cap | €20.59b |
| Earnings (TTM) | €263.90m |
| Revenue (TTM) | €2.95b |
Is DIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIM income statement (TTM) | |
|---|---|
| Revenue | €2.95b |
| Cost of Revenue | €1.60b |
| Gross Profit | €1.34b |
| Other Expenses | €1.08b |
| Earnings | €263.90m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.71 |
| Gross Margin | 45.64% |
| Net Profit Margin | 8.96% |
| Debt/Equity Ratio | 58.8% |
How did DIM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/24 00:15 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sartorius Stedim Biotech S.A. is covered by 33 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Julien Dormois | BNP Paribas Exane |